GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Research & Development

Kolon Life Science (XKRX:102940) Research & Development : ₩14,982 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Kolon Life Science's Research & Development for the three months ended in Mar. 2024 was ₩3,825 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ₩14,982 Mil.

Kolon Life Science Research & Development Historical Data

The historical data trend for Kolon Life Science's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Research & Development Chart

Kolon Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,490.33 13,154.48 14,327.20 13,583.00 14,891.89

Kolon Life Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,735.06 3,608.84 3,949.42 3,598.57 3,825.22

Kolon Life Science Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩14,982 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kolon Life Science  (XKRX:102940) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kolon Life Science Research & Development Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Kolon Life Science (XKRX:102940) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Research & Development
Comparable Companies
XKRX:008490 XKRX:003220 XKRX:058820 XKRX:047920 XKRX:005500 XKRX:033270 XKRX:092040 XKRX:000020 XKRX:200670 XKRX:206650 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Website
http://www.kolonls.co.kr
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines